Home

Partners for Continued Excellence

HealthCore Academy is a pioneer in leading and setting industry standards that are internationally accredited.

Accredited & Endorsed

Workshops and trainings by HealthCore Academy receive the support of the Department of Health and other government agencies as well as various medical societies.

Anywhere

Going digital allows participants to join from anywhere, be it at the office or at home.

World-class

Bringing you world-class standards and best practices through workshops and trainings.

Online Events

Offering you a powerful platform to learn, attend, and complete entire certification courses.

Consulting

For more specific requirements, we organize curated events to provide insights on international standards.

Earning Units

Selected workshops and events offer participants the opportunity to earn professional CPD Units.

Upcoming Events

13 Lessons
55 Students

Developing and Implementing an Effective Antimicrobial Stewardship Program in Hospitals Course Description The World Health Organization (WHO) has …

13 Lessons
55 Students

This workshop will discuss various Facility Management and Safety issues that cover important topics such as: Leadership …

18 Lessons
59 Students

This workshop will discuss various Facility Management and Safety issues that cover important topics such as: Leadership …

95 Students

How do we ensure that the hospital building is safe and has the ability to offer uninterrupted care …

To Thrive In HealthCare Today, You’ll Need a Good Plan

How can we help?

HealthCore Academy works with internationally accredited partners to design programs that have world-class standards in healthcare and patient safety.

Each program is created with the Philippine setting in mind on how to further improve and better the industry in the country as a whole through triained and capable medical professionals.

What can we do with professional units?

Our programs offer participants the opportunity to earn PMA-CPD Units that can be added to your professional profile.

It provides you the best opportunity in having the best and up-to-date knowledge and skills required to best execute your practice and services.

Industry sought after

What makes our programs worth attending?

The topics chosen were varied, timely and practically useful for our operations

With more than 15 topics stretched out in 3 days, these were subjects we could use and apply in our clinics and wards, and even during the accreditation visits of DOH and PhilHealth
Dr. Rito Asilo I
Hospital Administrator of Asilo Hospital

Speakers were well spoken and knowledgeable

The speakers were well spoken and knowledgeable with the topics assigned; were able to address questions in forums, approachable as well
Dulce Lyn Quidet
Registered Nurse

excellent job in program presentation

The organizing team did an excellent job in program presentation, well planned and delivered clearly its main purpose.
Vanessa Delemios
Laoratory Manager

Experts in the Field

The speakers are all experts in the field of ISO accreditation.
Charity Jomento
Quality Assurance Officer

Not an easy task

Not an easy task but somehow the people behind the event were able to push it through
Dr. Venus Agullo
Medical Officer, Valenzuela Medical Center

Speakers are very generous

Speakers are very generous in sharing their expertise and I think that is one of the best ways how our healthcare ecosystem would nurture and grow. Feels like I am attending a physical seminar. Good job.
Aubrey Hyacinth Ramirez
Infection Control Supervisor, Marikina Valley Medical Center

Speakers were concise, knowledgeable

All the speakers were concise, knowledgeable, and knew how to present their topics in a way that we could all understand it. It's a difficult feat simplifying such complex and difficult topics.
Dr. Kathleen Tulas
Medical Officer, DOH CHD CAR

Thankful for this opportunity

We are very thankful for this opportunity to attend such a very informative webinar
Gemma Osunero
RN, MAN, Chief Nurse, Imus Family Hospital

Stay Up-to-Date

Enter your email address to register to our newsletter subscription
delivered on a regular basis!

The international and intercontinental spread and expansion of antimicrobial-resistant Salmonella Typhi: a genomic epidemiology study

Background The emergence of increasingly antimicrobial-resistant Salmonella enterica serovar Typhi (S Typhi) threatens to undermine effective treatment and control. Understanding where antimicrobial resistance in S Typhi is emerging and spreading is crucial towards formulating effective control strategies. Methods In this genomic epidemiology study, we sequenced the genomes of 3489 S Typhi strains isolated from prospective enteric fever surveillance studies in Nepal, Bangladesh, Pakistan, and India (between 2014 and 2019), and combined these with a global collection of 4169 S Typhi genome sequences isolated between 1905 and 2018 to investigate the temporal and geographical patterns of emergence and spread of antimicrobial-resistant S Typhi. We performed non-parametric phylodynamic analyses to characterise changes in the effective population size of fluoroquinolone-resistant, extensively drug-resistant (XDR), and azithromycin-resistant S Typhi over time. We inferred timed phylogenies for the major S Typhi sublineages and used ancestral state reconstruction methods to estimate the frequency and timing of international and intercontinental transfers. Findings Our analysis revealed a declining trend of multidrug resistant typhoid in south Asia, except for Pakistan, where XDR S Typhi emerged in 2016 and rapidly replaced less-resistant strains. Mutations in the quinolone-resistance determining region (QRDR) of S Typhi have independently arisen and propagated on at least 94 occasions, nearly all occurring in south Asia. Strains with multiple QRDR mutations, including triple mutants with high-level fluoroquinolone resistance, have been increasing in frequency and displacing strains with fewer mutations. Strains containing acrBmutations, conferring azithromycin resistance, emerged in Bangladesh around 2013 and effective population size of these strains has been steadily increasing. We found evidence of frequent international (n=138) and intercontinental transfers (n=59) of antimicrobial-resistant S Typhi, followed by local expansion and replacement of drug-susceptible clades. Interpretation Independent acquisition of plasmids and homoplastic mutations conferring antimicrobial resistance have occurred repeatedly in multiple lineages of S Typhi, predominantly arising in south Asia before spreading to other regions. This article was originally published at The Lancet by Kesia Esther da Silva, PhD; Arif Mohammad Tanmoy, MSc ;Agila Kumari Pragasam, PhD ;Junaid Iqbal, PhD ;Mohammad Saiful Islam Sajib, MSc ;Ankur Mutreja, PhD Link to original article: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00093-3/fulltext#main-menu

Read More »

An Ancient Killer Is Rapidly Becoming Resistant to Antibiotics, Scientists Warn by HealthCore Academy

Typhoid fever might be rare in developed countries, but this ancient threat, thought to have been around for millennia, is still very much a danger in our modern world. According to new research, the bacterium that causes typhoid fever is evolving extensive drug resistance, and it’s rapidly replacing strains that aren’t resistant. Currently, antibiotics are the only way to effectively treat typhoid, which is caused by the bacterium Salmonella enterica serovar Typhi (S Typhi). Yet over the past three decades, the bacterium’s resistance to oral antibiotics has been growing and spreading. Sequencing the genomes of 3,489 S Typhi strains contracted from 2014 to 2019 in Nepal, Bangladesh, Pakistan, and India, researchers found a recent rise in extensively drug-resistant (XDR) Typhi.  XDR Typhi is not only impervious to frontline antibiotics, like ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole, but it is also growing resistant to newer antibiotics, like fluoroquinolones and third-generation cephalosporins. Even worse, these strains are spreading globally at a rapid rate. While most XDR Typhi cases stem from south Asia, researchers have identified nearly 200 instances of international spread since 1990.  Most strains have been exported to Southeast Asia, as well as East and Southern Africa, but typhoid superbugs have also been found in the United Kingdom, the United States, and Canada. “The speed at which highly-resistant strains of S. Typhi have emerged and spread in recent years is a real cause for concern, and highlights the need to urgently expand prevention measures, particularly in countries at greatest risk,” says infectious disease specialist Jason Andrews from Stanford University. Scientists have been warning about drug-resistant typhoid for years now, but the new research is the largest genome analysis on the bacterium to date. In 2016, the first XDR typhoid strain was identified in Pakistan. By 2019, it had become the dominant genotype in the nation. Historically, most XDR typhoid strains have been fought with third-generation antimicrobials, like quinolones, cephalosporins, and macrolides. But by the early 2000s, mutations that confer resistance to quinolones accounted for more than 85 percent of all cases in Bangladesh, India, Pakistan, Nepal, and Singapore. At the same time, cephalosporin resistance was also taking over. Today, only one oral antibiotic is left: the macrolide, azithromycin. And this medicine might not work for much longer. The new study found mutations that confer resistance to azithromycin are now also spreading, “threatening the efficacy of all oral antimicrobials for typhoid treatment”. While these mutations have not yet been adopted by XDR S Typhi, if they are, we are in serious trouble. If untreated, up to 20 percent of typhoid cases can be fatal, and today, there are 11 million cases of typhoid a year. Future outbreaks can be prevented to some extent with typhoid conjugate vaccines, but if access to these shots is not expanded globally, the world could soon have another health crisis on its hands. “The recent emergence of XDR and azithromycin-resistant S Typhi creates greater urgency for rapidly expanding prevention measures, including use of typhoid conjugate vaccines in typhoid-endemic countries,” the authors write. “Such measures are needed in countries where antimicrobial resistance prevalence among S Typhi isolates is currently high, but given the propensity for international spread, should not be restricted to such settings.” South Asia might be the main hub for typhoid fever, accounting for 70 percent of all cases, but if COVID-19 has taught us anything, it is that disease variants in our modern, globalized world are easily spread. To prevent that from happening, health experts argue nations must expand access to typhoid vaccines and invest in new antibiotic research. One recent study in India, for instance, estimates that if children are vaccinated against typhoid in urban areas, it could prevent up to 36 percent of typhoid cases and deaths. Pakistan is currently leading the way on this front. It is the first nation in the world to offer routine immunization for typhoid. Last year, millions of children were administered the vaccine, and health experts argue more nations need to follow suit. Antibiotic resistance is one of the world’s leading causes of death, claiming the lives of more people than HIV/AIDS or malaria. Where available, vaccines are some of the best tools we have to prevent future catastrophe. We don’t have time to waste. The study was published in The Lancet Microbe. This articles was originally published at Science Alert by Carly Cassella. Link to original article: https://www.sciencealert.com/a-medieval-killer-is-rapidly-becoming-resistant-to-more-antibiotics

Read More »